Home

Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)

376.89
+7.05 (1.91%)
NASDAQ · Last Trade: Aug 18th, 2:48 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close369.84
Open354.56
Bid376.14
Ask377.00
Day's Range351.31 - 376.89
52 Week Range200.63 - 377.46
Volume469,724
Market Cap6.45B
PE Ratio (TTM)-29.61
EPS (TTM)-12.7
Dividend & YieldN/A (N/A)
1 Month Average Volume420,903

Chart

About Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)

Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for liver and metabolic diseases, with an emphasis on addressing non-alcoholic steatohepatitis (NASH) and related conditions. The company’s research and development efforts center around its proprietary drug candidates that target and modulate key metabolic pathways, aiming to improve patient outcomes and provide effective treatment options. By leveraging cutting-edge science and clinical expertise, Madrigal is dedicated to advancing its pipeline of transformative therapies to meet the growing needs of patients suffering from complex liver diseases. Read More

News & Press Releases

Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharmainvestors.com
The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug.
Via Investor's Business Daily · August 18, 2025
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Diseasebenzinga.com
FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.
Via Benzinga · August 18, 2025
Billionaire Investor Buys Google And This Gold Miner Stockbenzinga.com
John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet.
Via Benzinga · August 16, 2025
Madrigal (MDGL) Q2 Revenue Soars 1,313%fool.com
Via The Motley Fool · August 5, 2025
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Saleschartmill.com
Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market.
Via Chartmill · August 5, 2025
Earnings Scheduled For August 5, 2025benzinga.com
Via Benzinga · August 5, 2025
Earnings Scheduled For May 1, 2025benzinga.com
Via Benzinga · May 1, 2025
Why Madrigal Pharmaceuticals Stock Is Soaring Todayfool.com
Via The Motley Fool · February 26, 2025
Earnings Scheduled For February 26, 2025benzinga.com
Via Benzinga · February 26, 2025
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drugbenzinga.com
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.
Via Benzinga · June 20, 2025
5 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · June 20, 2025
2 Monster Stocks in the Making to Buy Now and Hold for 10 Yearsfool.com
Via The Motley Fool · May 13, 2025
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stockstocktwits.com
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment, Rezdiffra.
Via Stocktwits · May 11, 2025
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Previewbenzinga.com
Via Benzinga · April 30, 2025
Why Madrigal Pharmaceuticals Stock Is Sinking Todayfool.com
Via The Motley Fool · January 13, 2025
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · April 25, 2025
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · February 26, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · February 26, 2025
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosisbenzinga.com
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.
Via Benzinga · February 26, 2025
8 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · January 20, 2025
Why Madrigal Pharmaceuticals Stock Was Plummeting This Weekfool.com
Via The Motley Fool · January 17, 2025
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.
Via MarketBeat · December 18, 2024
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analystfool.com
Via The Motley Fool · November 25, 2024
Top 3 Health Care Stocks That May Dip This Monthbenzinga.com
Via Benzinga · November 25, 2024
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Movefool.com
Via The Motley Fool · November 23, 2024